Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease
This treatment has been approved for sale to the public.
Information provided by (Responsible Party):
First received: August 5, 2009
Last updated: February 19, 2014
Last verified: February 2014
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This treatment has been approved for sale to the public.|
|Estimated Study Completion Date:||No date given|
|Estimated Primary Completion Date:||No date given|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Pastores GM, Rosenbloom B, Weinreb N, Goker-Alpan O, Grabowski G, Cohn GM, Zahrieh D. A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability. Genet Med. 2014 May;16(5):359-66. doi: 10.1038/gim.2013.154. Epub 2013 Nov 21.